Zacks Investment Research
03 Nov 2026, 19:35 UTC · 1h ago
Impact · against what's priced in
Vertex Pharmaceuticals' modest revenue beat and guidance raise are offset by an earnings miss and declining year-over-year profitability. While the CF franchise and CASGEVY momentum are positive, the higher operating expenses present a headwind to near-term EPS.
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Vertex reported third-quarter 2026 non-GAAP earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 by 3.25%.
Newreported November 03, 2026
So whatThe $0.16 per share miss combined with year-over-year earnings decline may lead analysts to revise FY2026 EPS estimates downward.
More negative than 87% of claims this week
Continue reading
5 related stories
Vertex increased its full-year 2026 revenue forecast to $13.15-$13.25 billion from $13.1-$13.2 billion.
Newreported November 03, 2026
So whatThe $50 million to $100 million increase in the top-line guide is driven by the $40-$50 million contribution from PALSONIFY.
More positive than 61% of claims this week
Quarterly revenues were $3.44 billion, surpassing the Zacks Consensus Estimate of $3.40 billion by approximately 1.2%.
Newreported November 03, 2026
So whatThe 12% year-over-year growth suggests the CF franchise remains a strong engine despite newer therapy scaling.
More positive than 47% of claims this week
CASGEVY revenues reached $99 million, representing a 30% sequential increase.
Newreported November 03, 2026
So whatCurrent momentum suggests the company is on track to meet its combined $500 million FY2026 goal for CASGEVY and JOURNAVX.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 44% of ticker scores this week
The company reported double-digit revenue growth and raised full-year guidance, though it missed earnings estimates and faced higher operating expenses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
